BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20042715)

  • 1. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
    Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
    J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
    Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
    Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
    Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
    Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HE4 combined with CA125: favorable screening tool for ovarian cancer.
    Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
    Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
    Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
    Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
    Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
    Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
    Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
    Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
    Hellstrom I; Hellstrom KE
    Adv Exp Med Biol; 2008; 622():15-21. PubMed ID: 18546615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
    Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW
    J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HE4 can help discriminate women with malignant ovarian 
tumors only if CA125 levels are elevated.
    Pitta Dda R; Sarian LO; Campos EA; Andrade LL; Sallum LF; Bragança JF; Campos Cde M; Derchain S
    Int J Biol Markers; 2013; 28(4):e377-86. PubMed ID: 23828407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.